FGF23 facilitates IL-1β synthesis in rheumatoid arthritis through activating PI3K, Akt, and NF-κB pathways.
Sung-Lin HuLouis Anoop ThadevoosTrung-Loc HoYen-You LinHsien-Te ChenChien-Chung HuangChen-Ming SuChih-Hsin TangPublished in: Environmental toxicology (2024)
Rheumatoid arthritis (RA) is a well-known autoimmune disorder related with joint pain, joint swelling, cartilage and bone degradation as well as deformity. Fibroblast growth factor 23 (FGF23) is an endocrine factor of the FGF family primarily produced by osteocytes and osteoblasts, involves an essential effect in pathogenesis of RA. IL-1β is a vital proinflammatory factor in the development of RA. However, the role of FGF23 on IL-1β synthesis in RA has not been fully explored. Our analysis of database revealed higher levels of FGF23 and IL-1β in RA samples compared with healthy controls. High-throughput screening demonstrated that IL-1β is a potential candidate factor after FGF23 treatment in RA synovial fibroblasts (RASFs). FGF23 concentration dependently promotes IL-1β synthesis in RASFs. FGF23 enhances IL-1β expression by activating the PI3K, Akt, and NF-κB pathways. Our findings support the notion that FGF23 is a promising target in the remedy of RA.
Keyphrases
- rheumatoid arthritis
- disease activity
- signaling pathway
- pi k akt
- ankylosing spondylitis
- interstitial lung disease
- cell proliferation
- emergency department
- chronic pain
- systemic lupus erythematosus
- spinal cord injury
- risk assessment
- immune response
- inflammatory response
- spinal cord
- body composition
- long non coding rna
- idiopathic pulmonary fibrosis